合心爽与倍他乐克联合治疗不稳定型心绞痛临床研究  

Clinical Research of Diltiazem Hydrochloride Tablets in Combination with Betaloc in UPA Treatment

作　　者：林宇彪[1] 

机构地区：[1]广东省吴川市人民医院,广东吴川524500

出　　处：《临床医学工程》2010年第10期52-53,共2页Clinical Medicine & Engineering

摘　　要：目的探讨合心爽与倍他乐克治疗不稳定型心绞痛(UPA)的疗效和安全性。方法将UPA患者随机分为两组,治疗组65例,对照组63例,治疗组用合心爽30～60mg,1次/8h,倍他乐克6.25～25mg,1次/12h,共7d;对照组用安慰剂口服,共7d。结果治疗组疗效明显优于对照组,治疗组总有效率95.4%,对照组总有效率85.7%,两组在疗效上差异有统计学意义(P<0.05)。结论治疗组比对照组起效快、作用强、效果好、安全性可靠。Objective To investigate the efficacy and safety of diltiazem hydrochloride tablets in combination with betaloc for the treatment of UPA. Methods The UPA patients were divided into two groups stochastically： the treatment group（n=65） and the control group（n=63） . The patients in the treatment group took 30 ～ 60 mg diltiazem hydrochloride tablets once eight hours and 6.25 ～ 25 mg betaloc once twelve hours for a week. The patients in the control group took placebo for a week. Results Therapeutic outcome of the treatment group was obviously better than that of the control group with the cure rate 95.4% v 85.7%,there was significant difference between the two groups（P 0.05） . Conclusion The treatment in the first group gets a quicker,stronger and better effect and is reliably safe.

关 键 词：合心爽 倍他乐克 不稳定型心绞痛 疗效 

分 类 号：R541.4[医药卫生—心血管疾病]